{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:05:25Z","timestamp":1780351525119,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Data"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a high need for predictive human <jats:italic>ex vivo<\/jats:italic> models for non-alcoholic fatty liver disease (NAFLD). About a decade ago, precision-cut liver slices (PCLSs) have been established as an <jats:italic>ex vivo<\/jats:italic> assay for humans and other organisms. In the present study, we use transcriptomics by\u00a0RNASeq to profile a new human and mouse PCLSs based assay for steatosis in NAFLD. Steatosis as quantified by an increase of triglycerides after 48\u2009h in culture, is induced by incremental supplementation of sugars (glucose and fructose), insulin, and fatty acids (palmitate, oleate). We mirrored the experimental design for human vs. mouse liver organ derived PCLSs and profiled each organ at eight different nutrient conditions after 24\u2009h and 48\u2009h time in culture. Thus, the provided data allows a comprehensive analysis of the donor, species, time, and nutrient factor specific regulation of gene expression in steatosis, despite the heterogeneity of the human tissue samples. Exemplified this is demonstrated by ranking homologous gene pairs by convergent or divergent expression pattern across nutrient conditions.<\/jats:p>","DOI":"10.1038\/s41597-023-02220-0","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T13:02:28Z","timestamp":1684501348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Transcriptomic profiling of induced steatosis in human and mouse precision-cut liver slices"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-3830","authenticated-orcid":false,"given":"Eric","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6794-7694","authenticated-orcid":false,"given":"Maciej","family":"Motyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grietje H.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Rust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6182-8165","authenticated-orcid":false,"given":"Coralie","family":"Viollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Olinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Oldenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"2220_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jhep.2007.06.020","volume":"47","author":"S Zelber-Sagi","year":"2007","unstructured":"Zelber-Sagi, S. et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study. J Hepatol 47, 711\u2013717 (2007).","journal-title":"J Hepatol"},{"key":"2220_CR2","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/hep.1840120505","volume":"12","author":"IR Wanless","year":"1990","unstructured":"Wanless, I. R. & Lentz, J. S. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 12, 1106\u20131110 (1990).","journal-title":"Hepatology"},{"key":"2220_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo, P. Nonalcoholic Fatty Liver Disease. New Engl J Medicine 346, 1221\u20131231 (2002).","journal-title":"New Engl J Medicine"},{"key":"2220_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577\u20131586 (2016).","journal-title":"Hepatology"},{"key":"2220_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17460441.2018.1410135","volume":"13","author":"BK Cole","year":"2017","unstructured":"Cole, B. K., Feaver, R. E., Wamhoff, B. R. & Dash, A. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery. Expert Opin Drug Dis 13, 193\u2013205 (2017).","journal-title":"Expert Opin Drug Dis"},{"key":"2220_CR6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/nprot.2010.111","volume":"5","author":"IAM de Graaf","year":"2010","unstructured":"de Graaf, I. A. M. et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc 5, 1540\u20131551 (2010).","journal-title":"Nat Protoc"},{"key":"2220_CR7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jhep.2013.01.009","volume":"58","author":"P Olinga","year":"2013","unstructured":"Olinga, P. & Schuppan, D. Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol 58, 1252\u20133 (2013).","journal-title":"J Hepatol"},{"key":"2220_CR8","doi-asserted-by":"publisher","unstructured":"Bigaeva, E. et al. Transcriptomic characterization of culture-associated changes in murine and human precision-cut tissue slices. Arch Toxicol 1\u201335, https:\/\/doi.org\/10.1007\/s00204-019-02611-6 (2019).","DOI":"10.1007\/s00204-019-02611-6"},{"key":"2220_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1038\/nprot.2010.111","volume":"5","author":"IAM de Graaf","year":"2010","unstructured":"de Graaf, I. A. M. et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc 5, 1540\u20131551 (2010).","journal-title":"Nat Protoc"},{"key":"2220_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/nu11030507","volume":"11","author":"GH Prins","year":"2019","unstructured":"Prins, G. H. et al. A Pathophysiological Model of Non-Alcoholic Fatty Liver Disease Using Precision-Cut Liver Slices. Nutrients 11, 507 (2019).","journal-title":"Nutrients"},{"key":"2220_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.18632\/oncotarget.27506","volume":"11","author":"S Schlager","year":"2020","unstructured":"Schlager, S. et al. Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis. Oncotarget 11, 875\u2013890 (2020).","journal-title":"Oncotarget"},{"key":"2220_CR12","author":"E Simon","year":"2023","unstructured":"Simon, E., Motyka, M., Prins, G. H., Olinga, P. & Oldenburger, A. RNASeq profiling of induced steatosis in precision-cut liver slices. GEO. https:\/\/identifiers.org\/geo\/GSE200419 (2023)."},{"key":"2220_CR13","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.20301168","author":"E Simon","year":"2023","unstructured":"Simon, E. et al. Differential RNASeq profiling of induced steatosis in human and mouse precision-cut liver slices. figshare https:\/\/doi.org\/10.6084\/m9.figshare.20301168 (2023)."},{"key":"2220_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hep.28852","volume":"65","author":"TBM Hakvoort","year":"2017","unstructured":"Hakvoort, T. B. M. et al. Hepatology - 2016 - Hakvoort - Pivotal role of glutamine synthetase in ammonia detoxification.pdf. Hepatology 65, 281\u2013293 (2017).","journal-title":"Hepatology"},{"key":"2220_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0642-7","volume":"16","author":"S Busch","year":"2017","unstructured":"Busch, S. et al. Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts. Mol Cancer 16, 73 (2017).","journal-title":"Mol Cancer"},{"key":"2220_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3389\/fphys.2017.01026","volume":"8","author":"EGD Stribos","year":"2017","unstructured":"Stribos, E. G. D., Seelen, M. A., Goor, H., van, Olinga, P. & Mutsaers, H. A. M. Murine Precision-Cut Kidney Slices as an ex vivo Model to Evaluate the Role of Transforming Growth Factor-\u03b21 Signaling in the Onset of Renal Fibrosis. Front Physiol 8, 1026 (2017).","journal-title":"Front Physiol"},{"key":"2220_CR17","doi-asserted-by":"publisher","first-page":"L896","DOI":"10.1152\/ajplung.00084.2017","volume":"312","author":"HN Alsafadi","year":"2017","unstructured":"Alsafadi, H. N. et al. An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. Am J Physiol-lung C 312, L896\u2013L902 (2017).","journal-title":"Am J Physiol-lung C"},{"key":"2220_CR18","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak, M., Lefebvre, P. & Staels, B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol 62, 720\u2013733 (2015).","journal-title":"J Hepatol"},{"key":"2220_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni, M., Groothuis, G. M. M. & de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Met 2, 875\u2013894 (2006).","journal-title":"Expert Opin Drug Met"},{"key":"2220_CR20","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1194\/jlr.M071183","volume":"57","author":"S Takahashi","year":"2016","unstructured":"Takahashi, S. et al. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans[S]. J Lipid Res 57, 2130\u20132137 (2016).","journal-title":"J Lipid Res"}],"container-title":["Scientific Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41597-023-02220-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-023-02220-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41597-023-02220-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T13:11:27Z","timestamp":1684501887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41597-023-02220-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2220"],"URL":"https:\/\/doi.org\/10.1038\/s41597-023-02220-0","relation":{"references":[{"id-type":"uri","id":"https:\/\/identifiers.org\/geo\/GSE200419","asserted-by":"subject"},{"id-type":"doi","id":"10.6084\/m9.figshare.20301168","asserted-by":"subject"}]},"ISSN":["2052-4463"],"issn-type":[{"value":"2052-4463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"4 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ES, WR, SK, and AO are employees of Boehringer Ingelheim (BI). CV was employee of BI at the time when the work was performed. BI is a research oriented pharmaceutical company. All BI author declare no further conflicts of interest. MM is an employee of Ardigen and worked as such as a contractor for BI. GP, ML, and PO have no competing financial or non-financial interests that relate to their work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"304"}}